Babak Bamshad, MD
Pediatric Urology · Los Angeles, CANPI 1437282936
Payments from drug & device makers
Across 170 payments — averaging $25.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$1K
- Pfizer$768
- Astellas Pharma US Inc$434
- Teleflex LLC$284
- Urogen Pharma, Inc.$282
- Endo Pharmaceuticals Inc.$231
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,23998%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 48 | $1,035 |
| Pfizer | 28 | $768 |
| Astellas Pharma US Inc | 22 | $434 |
| Teleflex LLC | 2 | $284 |
| Urogen Pharma, Inc. | 4 | $282 |
| Endo Pharmaceuticals Inc. | 13 | $231 |
| Immunitybio, Inc. | 1 | $142 |
| Johnson & Johnson | 5 | $131 |
| Acerus Pharmaceuticals Corporation | 7 | $130 |
| Bayer | 4 | $111 |
| Myovant Sciences Inc. | 5 | $110 |
| Blue Earth Diagnostics | 3 | $102 |
| AbbVie | 4 | $85 |
| Sumitomo Pharma America, Inc. | 4 | $76 |
| Amgen | 2 | $60 |
| Boston Scientific | 3 | $54 |
| 180 Medical, Inc. | 1 | $29 |
| Olympus America Inc. | 1 | $28 |
| Ferring Pharmaceuticals Inc. | 1 | $26 |
| Urovant Sciences Inc | 2 | $25 |
| Merck | 1 | $25 |
| AstraZeneca | 1 | $24 |
| Convatec Inc. | 1 | $22 |
| Endo USA, Inc. | 1 | $20 |
| Caris MPI, Inc. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Tolmar, Inc. | 1 | $19 |
| Accord Healthcare, Inc. | 1 | $16 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$284
- JELMYTO$180
- Prolaris$149
- ANKTIVA$142
How this compares
$4,339 in reported general payments places this provider in the 75th percentile of 39 pediatric urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 37 | $524,585 |
| GemtesaVibegron | 309 | $241,394 |
| Lupron DepotLeuprolide Acetate | 27 | $53,895 |
| MyrbetriqMirabegron | 63 | $53,042 |
| Tadalafil | 71 | $17,768 |
| Tamsulosin Hcl | 987 | $14,414 |
| Dutasteride | 141 | $6,583 |
| EligardLeuprolide Acetate | 16 | $6,488 |
| Finasteride | 460 | $5,086 |
| Methenamine Hippurate | 80 | $4,868 |
| Bethanechol Chloride | 58 | $3,913 |
| Silodosin | 23 | $3,113 |
| Doxycycline Hyclate | 193 | $2,599 |
| Tolterodine Tartrate ErTolterodine Tartrate | 22 | $1,953 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 108 | $1,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $434 | $577,627100 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $76 | $241,394309 claims |
| AbbVieLupron Depot | $85 | $53,89527 claims |
| Tolmar Pharmaceuticals, Inc.Eligard | $16 | $6,48816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 39 pediatric urology providers in California.
Other pediatric urology in Los Angeles
- Kathy HuenLos Angeles$576
- Renea SturmLos Angeles$163
- Antoine KhouryOrange$103K
- Michael BishaiPasadena$74K
- William KennedyPalo Alto$33K
- David NudellSan Jose$10K
- Robert PanviniSan Jose$9K
- Chi LeeBerkeley$7K
- Sung ChoeWest Covina$6K
- Alireza AlamLong Beach$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.